Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 10/20 | 0.44 |
| ▸ | RAB9A | P51151 | 8/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3412178 | 0.76 | RAB9A (0.58) | NPC1RAB9ASMN1; SMN2BCHEKDM4E | |
| SCHEMBL2076567 | 0.73 | HSP90AA1 (0.57) | HSP90AA1HSP90AB1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL29966674 | 0.73 | NPC1 (0.63) | HSP90AA1HSP90AB1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3076524 | 0.73 | NPC1 (0.63) | HSP90AA1HSP90AB1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL29614829 | 0.73 | NPC1 (0.63) | HSP90AA1HSP90AB1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL29942654 | 0.73 | NPC1 (0.63) | HSP90AA1HSP90AB1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL29493733 | 0.71 | HSP90AA1 (0.45) | HSP90AA1HSP90AB1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4743371 | 0.71 | HSP90AA1 (0.45) | HSP90AA1HSP90AB1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL57728 | 0.71 | PDE10A (0.54) | HSP90AA1HSP90AB1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6291686 | 0.68 | NPC1 (0.53) | HSP90AA1HSP90AB1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| EP-2793881-A1 | ANTI-CANCER COMPOUNDS TARGETING RAL GTPASES AND METHODS OF USING THE SAME | The Regents of the University of Colorado (US) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013096820-A1 | ANTI-CANCER COMPOUNDS TARGETING RAL GTPASES AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2013-06-27 | — | — | WO | disclosed |
| US-20110294881-A1 | METHODS FOR TREATING LOWER URINARY TRACT DISORDERS USING alpha2delta SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS | EDUSA PHARMACEUTICALS, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| EP-1901775-B1 | KININ ANTAGONISTS FOR TREATING BLADDER DYSFUNCTION | JERINI AG (DE) | 2011-08-24 | — | — | EP | disclosed |
| US-20080275080-A1 | Methods for treating lower urinary tract disorders using alpha2delta subunit channel modulators with smooth muscle modulators | DYNOGEN PHARMACUETICALS, INC. (US) | 2008-11-06 | — | — | US | disclosed |
| US-20080221039-A1 | Kinin Antagonists For Treating Bladder Dysfunction | JERINI AG (DE) | 2008-09-11 | — | — | US | disclosed |
| EP-1937272-A2 | BENZODIAZEPINES AS HCV INHIBITORS | Tibotec Pharmaceuticals Ltd. (IE) | 2008-07-02 | — | — | EP | disclosed |
| US-20080085916-A1 | METHODS FOR TREATING LOWER URINARY TRACT DISORDERS USING ALPHA2DELTA SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS | DYNOGEN PHARMACEUTICALS, INC. (US) | 2008-04-10 | — | — | US | disclosed |
| EP-1901775-A2 | KININ ANTAGONISTS FOR TREATING BLADDER DYSFUNCTION | Jerini AG (DE) | 2008-03-26 | — | — | EP | disclosed |
| WO-2004084881-A1 | METHODS FOR TREATING FUNCTIONAL BOWEL DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS | DYNOGEN PHARMACEUTICALS, INC. (US) | 2004-10-07 | — | — | WO | disclosed |
| WO-2004084879-A1 | METHODS FOR TREATING LOWER URINARY TRACT DISORDERS USING SMOOTH MUSCLE MODULATORS AND ALPHA-2-DELTA SUBUNIT CALCIUM CHANNEL MODULATORS | DYNOGEN PHARMACEUTICALS, INC. (US) | 2004-10-07 | — | — | WO | disclosed |
| WO-2004084880-A1 | METHODS FOR TREATING PAIN USING SMOOTH MUSCLE MODULATORS AND α2δ SUBUNIT CALCIUM CHANNEL MODULATORS | DYNOGEN PHARMACEUTICALS, INC. (US) | 2004-10-07 | — | — | WO | disclosed |
| US-20040198822-A1 | Methods for treating lower urinary tract disorders using alpha2delta subunit calcium channel modulators with smooth muscle modulators | DYNOGEN PHARMACUETICALS, INC. (US) | 2004-10-07 | — | — | US | disclosed |
| WO-2004066987-A2 | USE OF SODIUM CHANNEL MODULATORS FOR TREATING GASTROINTESTINAL TRACT DISORDERS | DYNOGEN PHARMACEUTICALS, INC. (US) | 2004-08-12 | — | — | WO | disclosed |
| WO-2004066990-A2 | METHODS OF TREATING LOWER URINARY TRACT DISORDERS USING SODIUM CHANNEL MODULATORS | DYNOGEN PHARMACEUTICALS, INC. (US) | 2004-08-12 | — | — | WO | disclosed |
| EP-0213293-B1 | 11-Substituted 5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-ones, process for their preparation and medicaments containing them | Dr. Karl Thomae GmbH (DE) | 1992-01-02 | — | — | EP | disclosed |
| EP-0126366-B1 | QUATERNARY SALTS OF DIBENZO(1,4)DIAZEPINONE, PYRIDO-(1,4)BENZODIAZEPINONE, PYRIDO(1,5)BENZODIAZEPINONE DERIVATIVES AND PHARMACOLOGICAL ACTIVITY THEREOF | DOMPE' FARMACEUTICI S.p.A. (IT) | 1988-12-14 | — | — | EP | disclosed |
| US-4594190-A | Quaternary salts of dibenzo[1,4]diazepinones, pyrido-[1,4]benzodiazepinones, pyrido[1,5]benzodiazepinones with antiulcer, antisecretory, spasmolytic and antimusarinic activities | DOMPE' FARMACEUTICI S.P.A. (IT) | 1986-06-10 | — | — | US | disclosed |
| EP-0126366-A2 | Quaternary salts of dibenzo(1,4)diazepinone, pyrido-(1,4)benzodiazepinone, pyrido(1,5)benzodiazepinone derivatives and pharmacological activity thereof | DOMPE' FARMACEUTICI S.p.A. (IT) | 1984-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198822-A1 | Methods for treating lower urinary tract disorders using alpha2delta subunit calcium channel modulators with smooth muscle modulators | GABRB2, GABRD, GABRB3 | HSP90AA1 3080/4885HSP90AB1 2640/4885NPC1 3788/4885 |
| US-20080221039-A1 | Kinin Antagonists For Treating Bladder Dysfunction | BDKRB2, BDKRB1, F2R | HSP90AA1 2349/4885HSP90AB1 1976/4885NPC1 4755/4885 |
| US-20080085916-A1 | METHODS FOR TREATING LOWER URINARY TRACT DISORDERS USING ALPHA2DELTA SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS | GABRB2, GABRB3, GABRB1 | HSP90AA1 2770/4885HSP90AB1 2091/4885NPC1 3505/4885 |
| US-20080275080-A1 | Methods for treating lower urinary tract disorders using alpha2delta subunit channel modulators with smooth muscle modulators | GABRB2, GABRB3, GABRB1 | HSP90AA1 2568/4885HSP90AB1 1916/4885NPC1 3644/4885 |
| US-20110294881-A1 | METHODS FOR TREATING LOWER URINARY TRACT DISORDERS USING alpha2delta SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS | GABRB2, GABRB3, GABRB1 | HSP90AA1 2770/4885HSP90AB1 2091/4885NPC1 3505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.